IL-18: throwing off the shackles to boost anti-tumor immunity  

作　　者：Karen O.Dixon Vijay K.Kuchroo 

机构地区：[1]Ann Romney Center for Neurologic Diseases and Evergrande Center for Immunologic Diseases,Brigham and Women’s Hospital,Harvard Medical School,Boston,MA,USA

出　　处：《Cell Research》2020年第10期831-832,共2页细胞研究（英文版）

摘　　要：In a new study in Nature,Zhou et al.identify IL-18BP as a novel soluble immune checkpoint,and describe engineering of a decoy-resistant IL-18 to overcome this barrier and drive potent anti-tumor immunity.Cytokines are soluble molecules important in cell signaling and communication,with the ability to orchestrate the immune response in autoimmunity,infection and cancer.The discovery of the potent tumoricidal activity of interferons paved the way for intense clinical investigation of several inflammatory cytokines in preclinical models,including IFN-α1 and IL-2,2 with cytokine therapy historically being an important treatment modality for cancer.While the use of these cytokines was a significant milestone in cancer immunotherapy,as a monotherapy they have not fulfilled the promise of efficacy seen in preclinical models.

关 键 词：IMMUNITY al. DECOY 

分 类 号：R730.3[医药卫生—肿瘤]